Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
Open accessPreprint — published as 10.7554/elife.83201
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has significant antiviral activity in vivo is uncertain. Methods: In a multicentre open label, randomized, controlled adaptive platform trial, adult patients with early symptomatic COVID-19 were randomized to one of six treatment arms including high dose ivermectin (600µg/kg daily for seven days), the monoclonal antibodies casirivimab and imdevimab (600mg/600mg), and no study drug. Viral clearance rates were derived from daily duplicate oropharyngeal quantitative PCR measurements. This ongoing trial is registered at ClinicalTrials.gov ( NCT05041907 ). Results: Randomization to the ivermectin arm was stopped after enrolling 205 patients into all arms, as the prespecified futility threshold was reached. Compared with the no study drug arm, the mean estimated SARS-CoV-2 viral clearance following ivermectin was 9.1% slower [95%CI -27.2% to +11.8%; n=45 versus n=41], whereas in a preliminary analysis of the casirivimab/imdevimab arm it was 52.3% faster [95%CI +7.0% to +115.1%; n=10 (Delta variant) versus n=41]. Conclusions: High dose ivermectin did not have measurable antiviral activity in early symptomatic COVID-19. Measured in this way viral clearance rate is a valuable pharmacodynamic measure in assessing antiviral COVID-19 therapeutics in vivo . Funding: “Finding treatments for COVID-19: A phase 2 multi-centre adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic COVID-19 (PLAT-COV)” is funded by the Wellcome Therapeutics Accelerator (223195/Z/21/Z). Impact: Rate of viral clearance determined from daily duplicate oropharyngeal swabs over one week is an efficient measure of antiviral efficacy in early COVID-19 infection. High dose ivermectin did not demonstrate measurable antiviral activity in early symptomatic COVID-19 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“however, a phase 2 trial testing ivermectin, 600 μg/kg daily for 7 days, and assessing a virologic end point of oropharyngeal SARS-CoV-2 polymerase chain reaction test result did not show measurable antiviral activity and was stopped for futility.21”
From Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116846 · Cited by 1,231
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Xiao, J., Hooper, A. T., Hamilton, J. D., Musser, B. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108163 · Cited by 632
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
O’Brien, M. P., Forleo-Neto, E., Musser, B. J., Isa, F., Chan, K.-C., Sarkar, N., Bar, K. J., Barnabas, R. V., Barouch, D. H., Cohen, M. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109682 · Cited by 447
Bruel, T., Hadjadj, J., Maes, P., Planas, D., Seve, A., Staropoli, I., Guivel-Benhassine, F., Porrot, F., Bolland, W.-H., Nguyen, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01792-5 · Cited by 282
Effect of Early Treatment with Ivermectin among Patients with Covid-19
Reis, G., Silva, E. A. S. M., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., dos Santos, C. V. Q., Campos, V. H. S., Nogueira, A. M. R., de Almeida, A. P. F. G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115869 · Cited by 224
Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
Sigal, A., Milo, R., & Jassat, W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00720-5 · Cited by 210
COVID-19 therapeutics: Challenges and directions for the future
Robinson, P. C., Liew, D. F. L., Tanner, H. L., Grainger, J. R., Dwek, R. A., Reisler, R. B., Steinman, L., Feldmann, M., Ho, L.-P., Hussell, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119893119 · Cited by 161
Cited by
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.1650 · Cited by 79
Jittamala, P., Schilling, W. H., Watson, J. A., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P. J., Ekkapongpisit, M., Cruz, C. V., Callery, J. J., et al. (2022) · medRxiv · doi:10.1101/2022.10.17.22281161 · Cited by 11
“The primary outcome measure was the rate of viral clearance, expressed as a slope coefficient (28), and estimated under a Bayesian hierarchical linear model fitted to the daily log10 viral load measurements between days 0 and 7 (18 measurements per patient).”
MethodSelf-citationJittamala, P., Boyd, S., Schilling, W. H. K., et al. (2024) · medRxiv · doi:10.1101/2024.01.16.24301337 · Cited by 9
Self-citationJittamala, P., Boyd, S., Schilling, W. H., Watson, J. A., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E. M., Wongnak, P., Esper, L., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103036 · Cited by 12
Self-citationNaggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Lim, S. C., Cohen, J. B., Kavtaradze, D., Amon, A. P., Gabriel, A., Gentile, N., et al. (2022) · medRxiv · doi:10.1101/2022.12.15.22283488 · Cited by 7
“21 This dose was safe and generally well tolerated, with a higher prevalence of the known self-resolving visual disturbances in the intervention arm previously reported with similar doses of ivermectin for parasitic infections.”
Result
Metadata
- Authors
- Schilling, W. H., Jittamala, P., Watson, J. A., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J. J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., Sookprome, S., Poovorawan, K., Thaipadungpanit, J., Blacksell, S., Imwong, M., Tarning, J., Taylor, W. R., Chotivanich, V., Sangketchon, C., Ruksakul, W., Chotivanich, K., Teixeira, M. M., Pukrittayakamee, S., Dondorp, A. M., Day, N. P., Piyaphanee, W., Phumratanaprapin, W., & White, N. J.
- Affiliations
- Mahidol University (TH)
- Navamindradhiraj University (TH)
- Universidade Federal de Minas Gerais (BR)
- Corresponding author
- Schilling, William HK
- White, Nicholas J
- ORCID
- Schilling, William HK
- Jittamala, Podjanee
- Watson, James A
- Ekkapongpisit, Maneerat
- Siripoon, Tanaya
- Ngamprasertchai, Thundon
- Luvira, Viravarn
- Cruz, Cintia
- Callery, James J
- Boyd, Simon
- Ngernseng, Thatsanun
- Abdad, Mohammad Yazid
- Hanboonkunupakarn, Borimas
- Poovorawan, Kittiyod
- Thaipadungpanit, Janjira
- Blacksell, Stuart
- Imwong, Mallika
- Taylor, Walter RJ
- Sangketchon, Chunlanee
- Chotivanich, Kesinee
- Teixeira, Mauro M
- Pukrittayakamee, Sasithon
- Dondorp, Arjen M
- Day, Nicholas PJ
- Piyaphanee, Watcharapong
- Phumratanaprapin, Weerapong
- White, Nicholas J
- Venue
- eLife
- Publisher
- openRxiv
- Published
- 2022-07-19
- Volume
- 12
- ISSN
- 2050-084X (ISSN-L)
- PMC
- PMC9988254
- OpenAlex
- W4321366419
- Cited by
- 22
- References
- 19
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 4 · 2022: 2
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- eLife (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Wellcome Trust (223195/Z/21/Z)
- Connecticut Sea Grant, University of Connecticut
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- ivermectin, SARS-CoV-2, COVID-19 pandemic, antiviral activity, pharmacometrics, casirivimab, imdevimab, adaptive platform trial, Delta variant, futility of treatment, pharmacodynamics
- MeSH terms
- COVID-19, SARS-CoV-2, Adult, Antiviral Agents, Humans, Ivermectin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19. https://app.cochat.ai/papers/10.1101/2022.07.15.22277570
- The paper
- Schilling, W. H., Jittamala, P., Watson, J. A., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J. J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., . . . White, N. J. (2022). Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19. eLife. https://doi.org/10.1101/2022.07.15.22277570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.